Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Does bone marrow biopsy done at the end of induction factor into your decision?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASCO 2023?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
How should one approach an incidentally found T-cell gene arrangement?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
For AML patients, when do you stop antiinfective agents?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?